XUHC:F:F-Xtrackers (IE) Public Limited Company - Xtrackers MSCI USA Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 53.18

Change

-0.57 (-1.06)%

Market Cap

USD 0.85B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict
Created with Highstock 5.0.6

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
XUHC:F
Relative Returns (From:    To: 2025-04-02 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
SXR8:F iShares Core S&P 500 UCITS ETF..

+36.80 (+7.43%)

USD 108.00B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+2.23 (+4.92%)

USD 105.67B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+2.26 (+4.53%)

USD 104.83B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.80 (+5.94%)

USD 62.86B
VUSA:F Vanguard Funds Public Limited ..

+7.35 (+8.43%)

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

+10.50 (+5.18%)

USD 49.04B
XJSE:F Xtrackers II - Japan Governmen..

-0.18 (-2.40%)

USD 41.48B
0ZC:F Zscaler Inc

-15.48 (-9.11%)

USD 37.92B
BSND:F Danone SA

-0.20 (-1.45%)

USD 33.83B
VGWL:F Vanguard FTSE All-World UCITS ..

N/A

USD 24.77B

ETFs Containing XUHC:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.04% 48% F 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.04% 48% F 53% F
Trailing 12 Months  
Capital Gain -0.80% 25% F 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.80% 23% F 42% F
Trailing 5 Years  
Capital Gain 62.23% 50% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 62.23% 51% F 39% F
Average Annual (5 Year Horizon)  
Capital Gain 10.69% 70% C- 66% D+
Dividend Return 10.69% 68% D+ 58% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.53% 64% D 90% A-
Risk Adjusted Return 101.49% 90% A- 93% A
Market Capitalization 0.85B 71% C- 55% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike